SAN DIEGO, Aug 12, 2011 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA ) today announced that Robert E. Hoffman will rejoin Arena on August 29, 2011, as Vice President, Finance and Chief Financial Officer. Mr. Hoffman served in various financial positions with Arena for over 13 years before departing in March to work for a private biopharmaceutical company.
"Robert is a valuable leader who has been a key contributor to Arena," said Jack Lief, Arena's President and Chief Executive Officer. "Robert's return comes at an important time for Arena as we prepare to respond to the lorcaserin complete response letter."
Mr. Hoffman, 45, currently serves as a member of the Financial Accounting Standards Board's small business advisory committee and the steering committee of the Association of Bioscience Financial Officers. He is also a member and a former director and President of the San Diego Chapter of Financial Executives International.
"I look forward to again working closely with my colleagues to support Arena's efforts to seek FDA approval of lorcaserin and to advance select earlier-stage research and development programs," said Mr. Hoffman.
Mr. Hoffman previously served as Arena's Vice President, Finance and Chief Financial Officer from December 2005 to March 2011; Vice President, Finance and Chief Accounting Officer from June 2004 to December 2005; Vice President, Finance from April 2000 to June 2004; and Controller from August 1997 to April 2000.
About Arena PharmaceuticalsArena is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing oral drugs that target G protein-coupled receptors, an important class of validated drug targets, in four major therapeutic areas: cardiovascular, central nervous system, inflammatory and metabolic diseases. Arena's most advanced drug candidate is intended for w